Intern: Biophysical Characterization of AAVs
Posted on: 7 Feb 2021
Cambridge, MA
Job Description
Job Description
This is for a 12-week internship position from June August 2021.
Biogen is seeking a highly motivated intern to join its Analytical Development department focused on the biophysical characterization of gene therapy drug products. The intern will have the opportunity to further characterize gene therapy products in development at Biogen using an array of methods within the biophysical toolbox.
Position Description
The intern will use a variety of high-throughput biophysical techniques to assess the conformation of adeno-associated virus (AAV) products. The goal of the project is to characterize higher-order structural properties of AAVs. A variety of spectroscopic and calorimetric methods will be used including: Circular Dichroism (CD), FTIR, differential scanning calorimetry (DSC), intrinsic tryptophan fluorescence, and static and dynamic light scattering. The effects of DNA packaging on AAV structure and stability will be investigated.
Qualifications
To participate in the Biogen Internship Program, students must meet the following eligibility criteria:
* Legal authorization to work in the U.S.
* Grade point average of 3.2 or higher preferred
* At least 18 years of age prior to the scheduled start date
* Be currently enrolled in an accredited college or university
* Prior laboratory experience
Additional qualifications:
The ideal candidate should have an interest in learning and working in a laboratory and the flexibility to work remotely if needed. Good organization and communication skills are required. An ideal candidate would have experience working with spectroscopic techniques to characterize biomolecules.
Education
Enrolled in an accredited university with an engineering / science disciple. Graduate students and senior undergraduate students will be considered.
Additional Information
All your information will be kept confidential according to EEO guidelines.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
